These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 1534330)

  • 1. An abnormality of the growth hormone/insulin-like growth factor-I axis in women with polycystic ovary syndrome due to coexistent obesity.
    Slowinska-Srzednicka J; Zgliczynski W; Makowska A; Jeske W; Brzezinska A; Soszynski P; Zgliczynski S
    J Clin Endocrinol Metab; 1992 Jun; 74(6):1432-5. PubMed ID: 1534330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome.
    Dunaif A; Mandeli J; Fluhr H; Dobrjansky A
    J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism.
    Apter D; Bützow T; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1995 Oct; 80(10):2966-73. PubMed ID: 7559882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overnight secretion pattern of growth hormone, sex hormone binding globulin, insulin-like growth factor-1 and its binding protein in obese and non-obese women with polycystic ovarian disease.
    Insler V; Barash A; Shoham Z; Koistinen R; Seppala M; Hen M; Lunenfeld B; Zadik Z
    Isr J Med Sci; 1994 Jan; 30(1):42-7. PubMed ID: 7511134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
    Morales AJ; Laughlin GA; Bützow T; Maheshwari H; Baumann G; Yen SS
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome.
    Orio F; Palomba S; Colao A; Russo T; Dentico C; Tauchmanovà L; Savastano S; Nappi C; Sultan C; Zullo F; Lombardi G
    J Endocrinol Invest; 2003 Feb; 26(2):117-22. PubMed ID: 12739737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males.
    Vermeulen A; Kaufman JM; Giagulli VA
    J Clin Endocrinol Metab; 1996 May; 81(5):1821-6. PubMed ID: 8626841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twenty-four-hour serum growth hormone, insulin, C-peptide and blood glucose profiles and serum insulin-like growth factor-I concentrations in women with polycystic ovaries.
    Prelević GM; Wurzburger MI; Balint-Perić L; Ginsburg J
    Horm Res; 1992; 37(4-5):125-31. PubMed ID: 1490653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An abnormality of the growth hormone/insulin-like growth factor-I axis in women with polycystic ovary syndrome.
    Kazer RR; Unterman TG; Glick RP
    J Clin Endocrinol Metab; 1990 Oct; 71(4):958-62. PubMed ID: 2401719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correlation between hormonal and metabolic profiles in women with polycystic ovary syndrome].
    Esposito V; Federico P; Lo Iudice G; Rispoli C; Sabatino P; D'Alessandro B
    Minerva Endocrinol; 1992; 17(1):21-9. PubMed ID: 1495451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
    Procopio M; Invitti C; Maccario M; Grottoli S; Cavagnini F; Camanni F; Ghigo E
    Int J Obes Relat Metab Disord; 1995 Feb; 19(2):108-12. PubMed ID: 7735336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity.
    Maccario M; Tassone F; Gianotti L; Lanfranco F; Grottoli S; Arvat E; Muller EE; Ghigo E
    J Clin Endocrinol Metab; 2001 Jan; 86(1):167-71. PubMed ID: 11231996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced growth hormone (GH) responsiveness to GH-releasing hormone after dietary manipulation in obese and nonobese subjects.
    Kelijman M; Frohman LA
    J Clin Endocrinol Metab; 1988 Mar; 66(3):489-94. PubMed ID: 3127415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia.
    Dunaif A; Graf M; Mandeli J; Laumas V; Dobrjansky A
    J Clin Endocrinol Metab; 1987 Sep; 65(3):499-507. PubMed ID: 3305551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.
    Corpas E; Harman SM; Piñeyro MA; Roberson R; Blackman MR
    J Clin Endocrinol Metab; 1992 Aug; 75(2):530-5. PubMed ID: 1379256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The growth hormone response to growth hormone-releasing hormone is blunted in polycystic ovary syndrome: relationship with obesity and hyperinsulinaemia.
    Lanzone A; Villa P; Fulghesu AM; Pavone V; Caruso A; Mancuso S
    Hum Reprod; 1995 Jul; 10(7):1653-7. PubMed ID: 8582956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
    Cordido F; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects.
    Rasmussen MH; Hvidberg A; Juul A; Main KM; Gotfredsen A; Skakkebaek NE; Hilsted J; Skakkebae NE
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1407-15. PubMed ID: 7536210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
    Procopio M; Maccario M; Savio P; Valetto MR; Aimaretti G; Grottoli S; Oleandri SE; Baffoni C; Tassone F; Arvat E; Camanni F; Ghigo E
    Panminerva Med; 1998 Mar; 40(1):13-7. PubMed ID: 9573747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects.
    Lee EJ; Nam SY; Kim KR; Lee HC; Cho JH; Nam MS; Song YD; Lim SK; Huh KB
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2495-8. PubMed ID: 7629249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.